Myriad Genetics , Inc. (NASDAQ:MYGN) stock has reached a new 52-week low, touching down at $12.16, as the company faces a challenging market environment. According to InvestingPro data, technical ...

SALT LAKE CITY, Jan. 23, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, has launched a new educational website providing ...

Myriad Genetics (MYGN) announced a study revealing that more patients completed hereditary cancer testing when they used an online screening ...

Study showed online screening tool and patient education improved genetic testing completion rateSALT LAKE CITY, Jan. 21, ...

Genetic testing involves the detection of specific alleles, mutations, genotypes or karyotypes that are associated with heritable traits, diseases or predispositions to disease for the individual ...

SAN FRANCISCO — At the JP Morgan Healthcare Conference here on Wednesday, Myriad Genetics CEO Paul Diaz provided preliminary Q4 and full-year 2024 financial results, as well as full-year 2025 guidance ...

Myriad Genetics faces a tough year ahead with new policy changes. Learn why MYGN stock has cratered and if it's poised for ...

Myriad Genetics (NASDAQ:MYGN – Get Free Report) was upgraded by stock analysts at StockNews.com from a “hold” rating to a ...

Myriad Genetics, Inc. MYGN recently announced an agreement with Hannah Storm, a nationally renowned sports broadcaster who ...

SALT LAKE CITY, Jan. 09, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, announced an agreement with Hannah Storm, a nationally ...

was caught early due to additional screening, Storm aims to encourage discussions about hereditary cancers through her social media platforms. Myriad Genetics aims to improve patient care by ...